StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.55−0.27 (-9.57%)

Close on Nov 19, 2026Market cap $43.74MP/E –Yield –

Tonix Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tonix Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $29.10M, up 196.0% year over year. For fiscal 2025 it was $13.11M, up 29.8% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.11M+29.8%
FY2024Dec 31, 2024$10.09M+29.9%
FY2023Dec 31, 2023$7.77M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.54M+577.9%
Q1 FY2026Mar 31, 2026$6.88M+183.2%
Q4 FY2025Dec 31, 2025$5.39M+108.8%
Q3 FY2025Sep 30, 2025$3.29M+16.6%
Q2 FY2025Jun 30, 2025$2.00M-9.5%
Q1 FY2025Mar 31, 2025$2.43M-2.1%
Q4 FY2024Dec 31, 2024$2.58M-31.7%
Q3 FY2024Sep 30, 2024$2.82M-29.3%
Q2 FY2024Jun 30, 2024$2.21M–
Q1 FY2024Mar 31, 2024$2.48M–
Q4 FY2023Dec 31, 2023$3.78M–
Q3 FY2023Sep 30, 2023$3.99M–

More Tonix Pharmaceuticals figures

See a number that looks wrong?